Global In Vivo Preclinical Brain Imaging Devices Market, By Imaging Modality Type (MRI, PET/SPECT, CT, Optical Miniscopes, 2 Photon Confocal, US, NIR Fluorescence, OCT, Bioluminescence, and Others), Application (Drug Discovery, Disease Characterization, and Toxicology), Therapeutic Area (Alzheimer’s Disease, Parkinson's Disease, Oncology, and Other Therapeutic Areas), Biological Variable (BOLD, Oxygenation, Blood Flow, Microvessels, Neuronal Activity, and Soft Tissue), Temporal Format of Use (Under an Hour, Many Hours, and Longitudinal), End User (Pharma-Inhouse, CRO, Academia, and Others) - Industry Trends and Forecast to 2030.
In Vivo Preclinical Brain Imaging Devices Market Analysis and Size
The global in vivo preclinical brain imaging devices market plays a crucial role in advancing our understanding of the brain, neurological disorders, and drug development. In vivo preclinical brain imaging devices provide researchers with the tools to study the brain's structure and function in living animals. This is fundamental for advancing our understanding of brain physiology, cognition, and behavior. Pharmaceutical and biotechnology companies rely on preclinical brain imaging to assess the efficacy and safety of new drugs and therapies targeting neurological disorders, such as Alzheimer's disease, Parkinson's disease, and psychiatric conditions.
Data Bridge Market Research analyzes that the global in vivo preclinical brain imaging devices market is expected to reach the value of USD 1,124,983.68 thousand by 2030, at a CAGR of 5.9% during the forecast period.
This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Imaging Modality Type (MRI, PET/SPECT, CT, Optical Miniscopes, 2 Photon Confocal, US, NIR Fluorescence, OCT, Bioluminescence, and Others), Application (Drug Discovery, Disease Characterization, and Toxicology), Therapeutic Area (Alzheimer’s Disease, Parkinson's Disease, Oncology, and Other Therapeutic Areas), Biological Variable (BOLD, Oxygenation, Blood Flow, Microvessels, Neuronal Activity, and Soft Tissue), Temporal Format of Use (Under an Hour, Many Hours, and Longitudinal), End User (Pharma-Inhouse, CRO, Academia, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
PerkinElmer Inc., FUJIFILM Corporation, Mediso Ltd., Spectral Instruments Imaging, MR Solutions, Charles River Laboratories, Aspect Imaging Ltd., Bruker, Miltenyi Biotec, MILabs B.V., and Cubresa Inc.
|
Market Definition
In-vivo preclinical brain imaging devices are the tools employed in biomedical research to visualize and study the structure, function, and processes of the brain in living animals, typically rodents, such as mice and rats. These devices play a pivotal role in advancing the understanding of neurobiology, neurological diseases, and the development of potential therapies. They encompass a diverse range of technologies designed to non-invasively capture high-resolution images of the brain, providing researchers with invaluable insights into neural activity and pathology.
Global In Vivo Preclinical Brain Imaging Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Neurological Disorders
The growing prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and various neurodevelopmental disorders, has spurred heightened research efforts. Researchers are driven to better understand the underlying mechanisms, early detection, and potential treatments for these conditions.
There is a growing need for effective diagnostics, treatments, and interventions as the prevalence of neurological disorders continues to rise globally. In-vivo preclinical brain imaging devices are indispensable tools that contribute to a deeper understanding of these disorders and the development of innovative solutions, making them a vital component of the healthcare and research landscape.
Hence, the rising prevalence of neurological disorders is expected to drive the growth of the market in the forecast period.
- Advancements in Imaging Techniques Used in Brain Imaging
Advancements in imaging technologies have led to significantly improved spatial resolution and sensitivity in brain imaging. Higher-resolution images provide researchers with more detailed information about brain structures and functions. This improved clarity is essential for studying fine anatomical details and detecting subtle changes associated with neurological disorders or experimental treatments. Modern preclinical brain imaging devices often offer multi-modal capabilities, allowing researchers to combine multiple imaging techniques in a single study. For instance, combining magnetic resonance imaging (MRI) with positron emission tomography (PET) or single-photon emission computed tomography (SPECT) can provide complementary information about brain structure, metabolism, and function. This versatility enhances the depth and scope of preclinical research.
Advancements in functional brain imaging, such as functional MRI (fMRI) and PET, enable researchers to study brain activity in real time. This is crucial for understanding neural networks, cognitive processes, and how neurological disorders affect brain function. Functional imaging also plays a key role in evaluating the effectiveness of potential therapies. Dynamic imaging techniques, including dynamic contrast-enhanced MRI and dynamic PET, allow researchers to capture changes in brain physiology and function over time. These techniques are valuable for tracking disease progression and assessing the impact of interventions on dynamic processes such as blood flow, metabolism, and neurotransmitter activity.
Hence, advancements in surgical techniques are expected to drive the growth of the market in the forecast period.
Opportunity
Rising Strategic Initiatives by the Key Market Players
The in vivo preclinical brain imaging devices market is witnessing substantial growth due to the proactive strategic initiatives undertaken by the key market players. These initiatives are opening up opportunities for market expansion and advancement.
Strategic partnerships and collaborations between market leaders, academic institutions, research organizations, and pharmaceutical companies foster knowledge sharing and resource pooling. Such collaborations accelerate the development of cutting-edge imaging technologies and enhance the validation of new drug candidates using in vivo brain imaging.
In addition, expanding geographical reach by establishing global subsidiaries and distribution networks makes these devices more accessible to researchers and institutions worldwide. This expansion taps into emerging markets which leads neuroscience research and drug development on the rise.
Furthermore, customization of solutions and services tailored to specific research needs and diversified product portfolios cater to a broader range of customers, driving market growth by addressing diverse research requirements.
Thus, the above-mentioned proactive strategic initiatives by key market players may create opportunities for market growth, making advanced imaging technologies more accessible and precise for researchers and pharmaceutical companies.
Restraint / Challenge
Lack of Skilled Professionals Due to Technology Advancement
The in vivo preclinical brain imaging devices market is a critical segment within the broader field of medical imaging and neuroscience research. These devices play a pivotal role in advancing our understanding of brain function and disorders. However, the market's growth faces a significant challenge due to the scarcity of skilled professionals who can operate and interpret the data generated by these cutting-edge devices.
In-vivo preclinical brain imaging devices are advanced tools that utilize various imaging modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) to capture detailed images of the brain in living animals, usually rodents. These images help researchers study brain structure, function, and metabolism, facilitating the development of treatments for neurological disorders, such as Alzheimer's disease, Parkinson's disease, and schizophrenia.
One of the primary reasons why the lack of skilled professionals is a significant challenge for this market is the complexity of the technology involved. Operating and interpreting data from in vivo preclinical brain imaging devices requires a deep understanding of neuroanatomy, imaging physics, and data analysis techniques. Professionals need to be well-versed in the use of specialized software and possess strong analytical skills to make meaningful inferences from the images.
Furthermore, the field of neuroscience and neuroimaging is rapidly evolving, with new techniques and technologies constantly emerging. This necessitates continuous learning and adaptation by professionals to stay at the forefront of the field. As a result, there is a high demand for well-trained individuals who can keep up with the latest advancements and apply them effectively.
Thus, the scarcity of skilled professionals not only limits the adoption of these devices but also potentially hampers the quality of research and development efforts.
Recent Development
- In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue.
- In May 2022, FUJIFILM Corporation announced the launch of Vevo F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 features HD image processing technology and introduces a completely new signal pathway – from transducer to display screen. This enabled better image clarity, and when combined with multi-line processing, delivered significantly improved frame rates over earlier generation platforms.
- In April 2022, PerkinElmer, Inc. announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system. This increased the company's product portfolio and overall revenue.
- In December 2021, Battery Ventures, a global, technology-focused investment firm, acquired LI-COR Biosciences, an industry-leading company that makes highly engineered instrumentation systems for environmental research, agriculture, drug discovery, protein research, and therapeutics development.
- In October 2021, MR Solutions announced the launch of a new AI that revolutionizes Magnetic Resonance Imaging (MRI) for preclinical research. This helped the organization develop more revenue.
Global In Vivo Preclinical Brain Imaging Devices Market Scope
The global in vivo preclinical brain imaging devices market is segmented into six notable segments based on imaging modality type, application, therapeutic area, biological variable, temporal format of use, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Imaging Modality Type
- MRI
- PET/SPECT
- CT
- Optical Miniscopes
- 2 Photon Confocal
- US
- NIR Fluorescence
- OCT
- Bioluminescence
- Others
On the basis of imaging modality type, the market is segmented into MRI, PET/SPECT, CT, optical miniscopes, 2 photon confocal, US, NIR fluorescence, OCT, bioluminescence, and others.
Application
- Drug Discovery
- Disease Characterization
- Toxicology
On the basis of application, the market is segmented into drug discovery, disease characterization, and toxicology.
Therapeutic Area
- Alzheimer's Disease
- Parkinson's Disease
- Oncology
- Other Therapeutic Areas
On the basis of therapeutic area, the market is segmented into Alzheimer's disease, Parkinson's disease, oncology, and other therapeutic areas.
Biological Variable
- BOLD
- Oxygenation
- Blood Flow
- Microvessels
- Neuronal Activity
- Soft Tissue
On the basis of biological variable, the market is segmented into BOLD, oxygenation, blood flow, microvessels, neuronal activity, and soft tissue.
Temporal Format of Use
- Under an Hour
- Many Hours
- Longitudinal
On the basis of temporal format of use, the market is segmented into under an hour, many hours, and longitudinal.
End User
- Pharma-Inhouse
- CRO
- Academia
- Others
On the basis of end user, the market is segmented into pharma-inhouse, CRO, academia, and others.
Global In Vivo Preclinical Brain Imaging Devices Market Regional Analysis/Insights
Global in vivo preclinical brain imaging devices market is analyzed and market size insights and trends are provided by country, imaging modality type, application, therapeutic area, biological variable, temporal format of use, and end user.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
North America is dominating the market with the largest market share due to growing demand for brain imaging devices. U.S. is the dominating country in North America region due to rising technological advancements. Germany is the dominating country in Europe region due to rising adoption of in-vivo imaging systems. Japan is the dominating country in Asia-Pacific region due to rising prevalence of neurological disorders.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global In Vivo Preclinical Brain Imaging Devices Market Share Analysis
Global in vivo preclinical brain imaging devices market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the market are PerkinElmer Inc., FUJIFILM Corporation, Mediso Ltd., Spectral Instruments Imaging, MR Solutions, Charles River Laboratories, Aspect Imaging Ltd., Bruker, Miltenyi Biotec, MILabs B.V., and Cubresa Inc., among others.
SKU-